Key result
The combined use of new nuclear cardiology modalities with cardiovascular biomarkers can help establish prevention guidelines and classify high-risk subgroups needing treatment intervention.
Combined use of new nuclear cardiology modalities with biomarkers may help establish prevention guidelines and classify high-risk subgroups needing treatment intervention.
May inform prevention strategies and high-risk classification; leaves open need for prospective validation before clinical adoption.
Biomarkers are used for evaluation of the pathophysiological state, risk stratification, diagnostic tools, staging of a disease and responsiveness to treatment. Representative biomarkers used in cardiovascular diseases may include C-reactive protein (CRP) for inflammation, brain natriuretic peptide (BNP), atrial natriuretic peptide (ANP), aldosterone, renin for neurohumoral factors, plasminogen activator inhibitor type-1 (PAI-1) for fibrinolysis and endothelial function, d-dimer for thrombosis, urine albumin/creatinine ratio for renal glomerular endothelial function. Further addition of new biomarkers may increase the capacity to find high-risk patients with cardiovascular diseases. In this review we would like to introduce several representative biomarkers in the context of nuclear cardiology. With the advancement of new imaging modalities new biomarkers are readily available. Combined use of new nuclear cardiology modalities with biomarkers one would establish prevention guidelines and classify high-risk subgroups needing treatment intervention.
No takes yet. Share an insight, caveat, or question.
Fujii et al. (2016) conducted a review in Cardiovascular Diseases. Cardiovascular biomarkers was evaluated. The combined use of new nuclear cardiology modalities with cardiovascular biomarkers can help establish prevention guidelines and classify high-risk subgroups needing treatment intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: